Christopher Liu
Stock Analyst at LUCID CAPITAL MARKETS
(2.63)
# 2,141
Out of 4,918 analysts
6
Total ratings
66.67%
Success rate
17.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GNLX Genelux | Initiates: Buy | $10 | $3.51 | +184.90% | 1 | Jul 21, 2025 | |
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $3.36 | +435.71% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $24.26 | +11.29% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $77.76 | -45.99% | 1 | Aug 8, 2023 | |
| EXEL Exelixis | Initiates: Market Perform | $18 | $37.26 | -51.69% | 1 | Aug 8, 2023 |
Genelux
Jul 21, 2025
Initiates: Buy
Price Target: $10
Current: $3.51
Upside: +184.90%
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $3.36
Upside: +435.71%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $24.26
Upside: +11.29%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $77.76
Upside: -45.99%
Exelixis
Aug 8, 2023
Initiates: Market Perform
Price Target: $18
Current: $37.26
Upside: -51.69%